Abstract:Bladder cancer is the most common malignant tumour in the urinary tract. Approximately 75% of the cases are non-muscle-invasive cancers that can be treated with transurethral resection of the bladder (TURB). One fourth of the patients present with muscle-invasive tumours and require radical cystectomy, occasionally in combination with chemotherapy. In stage T1 bladder cancer, the tumour is not muscle-invasive but has invaded the basal membrane and thus has a high potential to progress to muscle-invasive cancer. In these cases, a secondlook resection should follow the primary TURB to ensure that all tumour tissue has been removed. Intravesical treatment with bacillus Calmette-Guérin (BCG) is recommended to prevent recurrence. Despite existing prognostic models based on clinical and morphological factors, especially in stage T1 bladder cancer, it is difficult to make correct assumptions regarding prognosis and optimal treatment. The aim of the research underlying this thesis was to elucidate various aspects of diagnosis and treatment of stage T1 bladder cancer. The first study used tumours from a previously investigated cohort of 237 patients with bladder cancer of all stages that had previously been classified into five molecular subtypes (urobasal A and B, genomically unstable, squamous carcinoma cell like, and infiltrated), to develop a classifier based on immunohistochemistry (IHC). This IHC classifier could reproduce the molecular subtypes in 88% of the cases. The subtypes were shown to have different biological properties and varying potential to progress. In the second study, this IHC classifier was used to subtype primary stage T1 bladder cancer tumours in a population-based cohort of 167 patients. The risk of progression to muscle-invasive disease depended on the molecular pathological subtype. Outcome was even more precisely predicted by using the molecular pathological subtype in combination with clinical factors or with information on immune response. In the third study, the use of second-look resection was investigated in a population-based cohort including all 910 patients diagnosed with stage T1 bladder cancer in Sweden in 20082009, and the results revealed substantial differences in the use of this procedure in the six healthcare regions. Bladder cancer death was more common in patients with than in those without remaining T1 tumour in their second-look specimens, but was noted even more often in patients that did not undergo second-look resection. Differences in bladder cancer death between healthcare regions could not be explained solely by the observed disparities in the use of second-look resection. The fourth investigation included all 3,758 patients diagnosed with stage T1 bladder cancer in Sweden in 1997-2006. The use of BCG during the study period increased from 18% in 1997-2000 to 31% in 2004-2006. Patients younger than 75 years, patients treated at high-volume hospitals, patients with grade 3 tumours, and patients from the northern, southern, and Uppsala/Örebro healthcare regions were more frequently treated with BCG. Rates of overall and cancer-specific survival were higher in patients treated with BCG and lower in patients that were ≥75 years of age and those with grade 3 tumours. From a population-based perspective, BCG was found to be underused in Sweden, especially in patients aged ≥75 years and those treated at low-volume hospitals.

Exogenous GTP increases cyclic GMP and inhibits thrombin-induced aggregation of washed human platelets: comparison with ATP, adenosine and guanosine.

Equilibria Data for the CO2 + Ethanol + Ketoprofen Systems – Experimental and Modeling

Solubility of Tiamulin Hydrogen Fumarate in Acetone, Acetonitrile, Ethyl Acetate, Ethyl Formate, and Butyl Acetate from (288.2 to 318.2) K

Solubility of 1-Fluoro-4-(methylsulfonyl)benzene in Five Pure Organic Solvents at Temperatures from (288.40 to 331.50) K

Solubilities of Polyhydroxybenzophenones in an Ethanol + Water Mixture from (293.15 to 343.15) K

Measurement, correlation of solubility and thermodynamic properties analysis of 5,5′-bis(2,4,6-trinitrophenyl)-2,2′-bis(1,3,4-oxadiazole) in different mono solvents

Enhancing Ketoprofen Solubility: A Strategic Approach Using Solid Dispersion and Response Surface Methodology

Role of solvent properties and composition on the solid-liquid equilibrium of trifloxystrobin and thermodynamic analysis

Experimental and Thermodynamic Analysis on the Solubility of Valsartan in Ethyl Acetate + (butanone, Isopropyl Ether) Binary Solvent Mixtures (from 278.15 to 323.15 K)

Ketoprofen-Tromethamine: Binary Phase Diagram of Multicomponent Crystal, Dissolution Rate, and Analgesic Activity Evaluation

Solubility Determination, Thermodynamic Modeling, and Solvent Effect of 2′,4′-Dihydroxyacetophenone in 10 Monosolvents and Two Binary Solvents from 293.15 to 333.15 K

Statin Use and Risk of Atrial Fibrillation or Flutter: A Population-based Case–Control Study

Solubility and Polymorphism of a HOF Monomer N 1 , N 3 , N 5 -Tris(pyridin-4-yl)benzene-1,3,5-tricarboxamide in 12 Neat Solvents at Temperatures from 283.15 to 323.15 K

Solubility Determination and Preferential Solvation of Diphenoxylate in Aqueous Cosolvent Solutions of Ethanol, Acetonitrile, Methanol, and Isopropanol

Photocatalytic Degradation of High Concentration Aqueous Solutions of Ketoprofen: Adsorption, Reaction Kinetic and Product Studies

Thermodynamic Analysis of the Solubility of Sulfadiazine in (Acetonitrile 1-Propanol) Cosolvent Mixtures from 278.15 K to 318.15 K

Stage T 1 Bladder Cancer – Aspects of Diagnosis and Treatment

Solubility measurement, modeling, and solvent effect of m-hydroxyacetophenone in ten pure and binary mixed solvents from T = (289.15–325.15) K

Development of ketoprofen-p-aminobenzoic acid co-crystal: formulation, characterization, optimization, and evaluation

Measurement and Thermodynamic Modeling of Oxaprozin Solubility in Polymers and Mixed Solutions

Molecular structure, spectroscopic (FT-IR, FT-Raman, NMR, UV-VIS), chemical reactivity and biological examinations of Ketorolac